ReportLinker Find Industry reports, Company profilesand Market Statistics
>> Get this Report Now by email!
Pharma and Biotech M&A Trends 2009-2014
Published on July 2014
Report Summary
The Pharma and Biotech M&A Trends 2009-2014 report provides comprehensive understanding and unprecedented access to the
merger and acquisition agreements entered into by the worlds leading biopharma companies. The report provides a detailed
understand and analysis of how and why companies enter merger and acquisition deals.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in
terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the
payments clauses, the devil is in the detail in terms of how payments are triggered ' contract documents provide this insight where
press releases and databases do not.
This report contains a comprehensive listing of all merger and acquisition deals announced since 2009 as recorded in the Current
Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual merger and
acquisition contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important
issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of M&A dealmaking and business activities. Chapter 1 provides an introduction
to the report, whilst chapter 2 provides an analysis of the trends in M&A as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of M&A deals. The chapter includes numerous case studies to enable understanding
of M&A deals.
Chapter 4 provides a review of the leading M&A deals since 2009. Deals are listed by headline value, signed by bigpharma and and
most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online
access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 50 big pharma companies (with M&A announements) with a brief summary
followed by a comprehensive listing of M&A deals available in the public domain. Where available, each deal title links via Current
Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each
contract document on demand.
Chapter 6 provides a comprehensive listing of the top 50 big biotech companies (with M&A announements) with a brief summary
followed by a comprehensive listing of M&A deals available in the public domain. Where available, each deal title links via Current
Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each
contract document on demand.
Chapter 7 provides a comprehensive and detailed review of M&A deals signed and announced since 2009 where a contract
document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with
respect to the M&A deal.
Pharma and Biotech M&A Trends 2009-2014 (From Issuu) Page 1/21
ReportLinker Find Industry reports, Company profilesand Market Statistics
>> Get this Report Now by email!
In addition the report includes a comprehensive listing of all M&A deals announced since 2009. Each listing is organized as an
appendix by company A-Z, and industry sector. Each deal title links via hyperlink to an online version of the deal record including,
where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in M&A dealmaking since 2009.
In conclusion, this report provides everything a prospective dealmaker needs to know about M&A alliances.
Table of Content
TABLE OF CONTENTS
Executive Summary
Chapter 1 ' Introduction
Chapter 2 ' Trends in M&A dealmaking
2.1. Introduction
2.2. Difference between merger and acquisition deals
2.3. Trends in M&A deals since 2009
2.3.1. Japanese M&A accelerates
2.3.2. Option to acquire the new acquisition'
2.3.3. Case study 1: Cephalon ' Ception
2.3.4. Case study 2: HertArt Aps ' Vitrolife
2.4. When M&A can be useful
2.5. Attributes of M&A deals
2.5.1. M&A as an alternative to IPO
2.6. Partnering deals with M&A component
2.6.1. Partnering as a precursor to M&A
2.6.1.a. Case study 3: Celgene ' VentiRx Pharmaceuticals, Oct 2012
2.6.2. Equity as part of partnering deal
2.6.2.a. Case study 4: BioMarin ' Catalyst Pharma Partners, Oct 2012
2.6.2.b. Case study 5: Pfizer ' Clovis Oncology , June 2011
2.6.2.c. Case study 6: Tesaro ' OPKO Health, December 2010
2.6.3. Conversion of partnership to acquisition
2.6.4. But M&A is not always the route followed
2.7. Big pharma mega mergers ' are we at the end of the road'
2.7.1. Growth of Johnson & Johnson through M&A
2.7.2. Growth of Novartis through M&A
2.8. Accessing innovation through M&A
2.8.1. Big pharma acquisitions of small companies
2.8.1.a. Case study 7: Abbott ' Facet Biotechnology
2.8.1.b. Case study 8: Gilead Sceinces ' Pharmasset
2.8.2. Medium and small biopharma ' use of M&A
2.8.2.a. Case study 9: Allergan ' MAP Pharmaceuticals
2.8.2.b. Case study 10: Reckitt Benckiser ' Schiff Nutrition International
2.8.3. Using M&A to build a company
2.8.3.a. Case study 11: Shire ' built from M&A
Pharma and Biotech M&A Trends 2009-2014 (From Issuu) Page 2/21
ReportLinker Find Industry reports, Company profilesand Market Statistics
>> Get this Report Now by email!
2.8.3.b. Case study 12: Zeneus - acquiring a ready-made European capability
2.8.3.c. Case study 13: Novartis ' from pure pharma to half generic
2.8.4. Emergence of biotech-biotech mergers
2.8.4.a. Case study 14: Merger between Biogen and Idec
2.8.4.b. Case study 15: Amgen acquisition activity
2.9. The emerging role of private equity in M&A
2.10. Implementing M&A transactions
2.11. Joint ventures as alternative to M&A
2.12. The future of M&A in biopharma
Chapter 3 ' Overview of M&A deal structure
3.1. Introduction
3.2. Pure versus multi-component acquisition deals
3.3. Pure M&A agreement structure
3.3.1. Example acquisition agreements
3.3.1.a. Case study 16: Allergan - SkinMedica ' November 2012
3.4. Acquisition as part of a wider alliance agreement
3.4.1. Example acquisition option clauses
3.4.1.a. Case study 17: MGI Pharma ' AkaRx ' October 2007
3.5. Merger agreements
3.5.1. Example merger agreements
3.5.1.a. Case study 18: Synergy Pharmaceuticals ' Callisto Pharmaceuticals ' July 2012
Chapter 4 ' Leading M&A deals
4.1. Introduction
4.2. Top M&A deals by value
4.3. Top merger deals
4.4. Most active M&A dealmakers
4.5. Big pharma M&A deal activity
4.6. Big biotech M&A deal activity
Chapter 5 ' Big pharma M&A deals
5.1. Introduction
5.2. How to use M&A deals
5.3. Big pharma company M&A deal profiles
Abbott
Abbvie
Actavis
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Pharma and Biotech M&A Trends 2009-2014 (From Issuu) Page 3/21
ReportLinker Find Industry reports, Company profilesand Market Statistics
>> Get this Report Now by email!
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Fresenius
Gilead Sciences
GlaxoSmithKline
Grifols
Hospira
Johnson & Johnson
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Mylan
Novartis
Otsuka
Pfizer
Roche
Sanofi
Servier
Shionogi
Shire
Sun Pharmaceutical
Takeda
Teva
UCB
Valeant
Chapter 6 ' Big biotech M&A deals
6.1. Introduction
6.2. How to use M&A deals
6.3. Big biotech company M&A deal profiles
3SBio
Acorda Therapeutics
Actelion
Alexion Pharmaceuticals
Alkermes
AMAG Pharmaceuticals
Anika Therapeutics
Bavarian Nordic
Pharma and Biotech M&A Trends 2009-2014 (From Issuu) Page 4/21
ReportLinker Find Industry reports, Company profilesand Market Statistics
>> Get this Report Now by email!
Biocon
BioMarin Pharmaceuticals
Cangene
Celgene
Cubist
Elan
Emergent BioSolutions
Enzo Biochem
Galapagos
Ipsen
Isis Pharmaceuticals
LFB Group
Morphosys
Onyx Pharmaceuticals
Optimer
Questcor Pharmaceuticals
SciClone Pharmaceuticals
Spectrum Pharmaceuticals
Swedish Orphan Biovitrum
The Medicines Company
United Therapeutics
Vertex Pharmaceuticals
ViroPharma
Chapter 7 ' M&A contracts directory
7.1. Introduction
7.2. Company A-Z
Abbott Laboratories
Abbvie
Abraxis BioScience
Abraxis Health
Accelerated Care Plus
AccelPath
Accelrys
Accuray
Acon Labs
Acorda Therapeutics
Actavis
Actavis (acquired by Watson)
Actinium Pharmaceuticals
Adamis Pharmaceuticals
Adeona Pharmaceuticals
Adolor
Advanced Biohealing
Advanced Medical Optics
Adventrx Pharmaceuticals
Aetna
AGA Medical
Agila Specialties
Pharma and Biotech M&A Trends 2009-2014 (From Issuu) Page 5/21
ReportLinker Find Industry reports, Company profilesand Market Statistics
>> Get this Report Now by email!
Agilent Technologies
Akorn
Albany Molecular Research
Aldagen
Alexion Pharmaceuticals
Alexza Pharmaceuticals
Alkermes
Allergan
Allezoe Medical
Allos Therapeutics
Allozyne
Alpha Innotech
Alphatec Spine
Alpine Biomed
Amag Pharmaceuticals
Amarin
American Medical Systems
Amerifit Brands
Amgen
Amorcyte
Amsterdam Molecular Therapeutics
Amylin Pharmaceuticals
Anchen Pharmaceuticals
Anesiva
ANI Pharmaceuticals
Anika Therapeutics
AorTx
Apax Partners
Applied Genomics
Aptalis Pharma
Apthera
AquaMed Technologies
Arcion Therapeutics
Ardea Biosciences
Arigene
Ariston Pharmaceuticals
Arrayit Diagnostics
Arresto BioSciences
Arrow Group
Arthrocare
Asahi Kasei
Ashland
Aspect Medical Systems
Assay Designs
AssuraMed
Astellas Pharma
Astex Pharmaceuticals
Astex Therapeutics
Pharma and Biotech M&A Trends 2009-2014 (From Issuu) Page 6/21
ReportLinker Find Industry reports, Company profilesand Market Statistics
>> Get this Report Now by email!
Astra Tech
AstraZeneca
Atlas Acquisition Corp
ATS Medical
Aurora Diagnostics
Avalon Pharmaceuticals
AVANYX Therapeutics
Avista Capital Partners
AxoGen
Azur Pharma
Banner Health
Bausch & Lomb
Baxter International
Bayer Healthcare
BBC Graphics
Beckman Coulter
Beijing Genomics Institute (BGI)
Belgian Volition
Bio-Imaging Technologies
BioClinica
Biocompatibles International
BioCryst Pharmaceuticals
Bioform Medical
BioMarin Pharmaceutical
BioMimetic Therapeutics
Bioniche Pharma
BioReliance
BioSante Pharmaceuticals
BioScrip
BioSphere Medical
Biotel
BioTelemetry
BioTime
Biovail
BioVectra
Biovex
Blackstone Lake Minerals
Bohai Pharmaceuticals Group
Boston Therapeutics
Bristol-Myers Squibb
BTG
Byrne Medical
Cactus Ventures
Cadence Pharmaceuticals
Cahaba Pharmaceuticals
Caleco Pharma
California Stem Cell
Caliper Life Sciences
Pharma and Biotech M&A Trends 2009-2014 (From Issuu) Page 7/21
ReportLinker Find Industry reports, Company profilesand Market Statistics
>> Get this Report Now by email!
Calistoga Pharmaceuticals
Calixa Therapeutics
Callisto Pharmaceuticals
Cambrex
Cambrex Zenara
Cambridge Research and Instrumentation
Canada Pension Plan Investment Board
Candela
Cantel Medical
Cape Cod Cardiac Cath
Cape Cod Cardiology Services
Cape Cod Hospital
Caraco Pharmaceuticals
Cardiac Science
Cardinal Health
CardioCORE Lab
Cardiogenesis
Cardiokine
Cardo Medical
CareDx
Celera
Celgene
Cell Biosciences
Cell Genesys
Cell Therapeutics
Celldex Therapeutics
Cellectar Biosciences
Cephalon
Ception Therapeutics
Cequent Pharmaceuticals
Cesca Therapeutics
Charles River Laboratories
Charterhouse Equity Partners
Chief Respect
Chiesi Farmaceutici
China Biopharmaceuticals
China Medicine Corporation
China PharmaHub
CitySync
Clarient
Claros Diagnostics
Clinical Data
CNS Wellness
CombinatoRx
Commonwealth Biotechnologies
Complete Genomics
Conceptus
Conmed
Pharma and Biotech M&A Trends 2009-2014 (From Issuu) Page 8/21
ReportLinker Find Industry reports, Company profilesand Market Statistics
>> Get this Report Now by email!
Cornerstone Therapeutics
Cortex Pharmaceuticals
Cougar Biotechnology
Covella Pharmaceuticals
Coventry Health Care
Covidien
CPEX Pharmaceuticals
Crealta Pharmaceuticals
Critical Homecare Solutions
Crucell
Cryolife
Cubist Pharmaceuticals
Curacyte Discovery
Curagen
Curaxis Pharmaceuticals
CV Therapeutics
CyDex
Cypress Pharmaceutical
Cyrenaic Pharmaceuticals
Cytomedix
Cytopia
Dainippon Sumitomo Pharma
Dako
Danaher
Dentsply International
Denville Scientific
Derma Sciences
Dermik Laboratories
Diagnostic Hybrids
Dialysis Corp of America
DigiPath Solutions
Dionex
Divine Skin Laboratories
Dragon Pharmaceutical
DS Healthcare
DSM
DUSA Pharmaceuticals
Dynavax Technologies
EKR Therapeutics
Elan
Elan Drug Technologies
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Endologix
Enobia Pharma
Enzo Biochem
Eon Labs
Pharma and Biotech M&A Trends 2009-2014 (From Issuu) Page 9/21
ReportLinker Find Industry reports, Company profilesand Market Statistics
>> Get this Report Now by email!
EpiCept
EQT
Ester Neurosciences
Etrials Worldwide
EUSA Pharma
Ev3
Excelsyn
Express Scripts
Facet Biotechnology
FasTrack Pharmaceuticals
Fero Industries
Fidia Advanced Biopolymers
Fidia Farmaceutici
FluoroPharma Medical
Footstar
Forest Laboratories
Forest Pharmaceuticals
Fujifilm
GE Healthcare
Gemin X Pharmaceuticals
Gen-Probe
Genentech
Generex Biotechnology
GeneSeek
GenturaDx
Genzyme
Gilead Sciences
GL Biochem
GlaxoSmithKline
Global Med Technologies
Global Medical Direct
Glycosan BioSystems
Grifols
GTC Biotherapeutics
Guangzhou LifeTech Pharmaceuticals
Haemonetics Corporation
Hanger Orthopedic Group
Hansen Medical
Hartlab
Harvard Bioscience
Hasco Medical
HealthTronics
Heart Hospital of Austin
HeartWare International
Hellman & Friedman
HepaLife
Hi-Tech Pharmacal
Hisamitsu Pharmaceutical
Pharma and Biotech M&A Trends 2009-2014 (From Issuu) Page 10/21
ReportLinker Find Industry reports, Company profilesand Market Statistics
>> Get this Report Now by email!
Hologic
Home Diagnostics
Hongshan Pharmaceuticals
Hospira
Human Genome Sciences
Huxley Pharmaceuticals
Hyaluron
Hypermarcas
I-Flow
Icagen
Idenix Pharmaceuticals
Ignyta
Illumina
Image Sensing Systems
ImaRX
IMMCO Diagnostics
Immucor
ImmuMetrix
Immune Pharmaceuticals
Immunovative Therapies
Impulse Monitoring
INC Research
Incline Therapeutics
Indevus Pharmaceuticals
Infinity Oil & Gas
Inhibitex
Innovus Pharmaceuticals
Inovio Biomedical
Insmed Inc
Inspire Pharmaceuticals
Intellipharmaceutics
International Specialty Products
InVentiv Health
Inverness Medical Innovations
InVivo
InVivo Therapeutics
ISTA Pharmaceuticals
Javelin Pharmaceuticals
Jazz Pharmaceuticals
Jefferies & Company
Johnson & Johnson
Juniper Investment Company
Kendle International
Kimberly-Clark
Kinetic Concepts
King Pharmaceuticals
Kinray
La Jolla Pharmaceutical
Pharma and Biotech M&A Trends 2009-2014 (From Issuu) Page 11/21
ReportLinker Find Industry reports, Company profilesand Market Statistics
>> Get this Report Now by email!
Laboratory Corporation of America
Lantis Laser
LEAD Therapeutics
LecTec
LEO Pharma
Lexicon Pharmaceuticals
LFB Biomedicaments
Life Technologies
Ligand Pharmaceuticals
Link Resources
Lipocine
LMA International
Luminex
MAKO Surgical
Mallinckrodt Pharmaceuticals
Manhattan Pharmaceuticals
Manhattan Scientifics
Mantecorp
MAP Pharmaceuticals
Martek Biosciences
Maya Medical
McKesson
MDRNA
Medarex
MedCath
Medco Health Solutions
MedEfficiency
Medical Developers
Medical Imaging
Medicis Pharma
MediVision Medical Imaging
MedServe
Medtox Scientific
Medtronic
Mepha Pharma
Merck and Co
Merck KGaA
Merge Healthcare
Merit Medical Systems
Merz
Metabasis Therapeutics
MIB Digital
Micro Beef Technologies
MicroFluidic Systems
Micromet
MidCap Financial
Millipore
Minerva Neurosciences
Pharma and Biotech M&A Trends 2009-2014 (From Issuu) Page 12/21
ReportLinker Find Industry reports, Company profilesand Market Statistics
>> Get this Report Now by email!
Monogram Biosciences
MorphoSys
Multigen Diagnostics
MWI Veterinary Supply
Mylan Laboratories
Myriad Genetics
Myriad Pharmaceuticals
Myriad RBM
Natus Medical
NBTY
Nellix
Neogen
NeoStem
Nepentes
Neurogen
Neuromed
Neuronex
NextRx
Nipro Corporation
North Horizon
Novartis
NovaVision
Novelos Therapeutics
Noven Pharmaceuticals
Novo Energies
NuPathe
Nurx Pharmaceuticals
NuVasive
Obagi Medical Products
Omthera Pharmaceuticals
One Lambda
Onyx Pharmaceuticals
Ophthalmic Imaging Systems
OPKO Health
Optimer Pharmaceuticals
Opto Circuits
Oracle Health Sciences
Orchid Cellmark
Orchid Chemicals and Pharma
Organ Transport Systems
Organovo
OrthoCyte
Orthohelix Surgical Designs
OSI Pharmaceuticals
Osteotech
Otix Global
Otsuka
OXiGENE
Pharma and Biotech M&A Trends 2009-2014 (From Issuu) Page 13/21
ReportLinker Find Industry reports, Company profilesand Market Statistics
>> Get this Report Now by email!
Paddock Laboratories
Papillon Holdings
Par Pharmaceutical
Parkway Clinical Laboratories
Pathfinder
Pathfinder Cell Therapy
PBM Products
Pearl Therapeutics
Penwest Pharmaceuticals
Peplin
PerkinElmer
Pernix Therapeutics
Perrigo
Pfizer
Phadia
Pharmasset
PharmaSwiss
PharmAthene
Phase Forward
PhotoMedex
Pier Pharmaceuticals
Piramal Healthcare
Poniard Pharmaceuticals
PositiveID
Power Medical Interventions
PPD
Presidio Pharmaceuticals
Prodesse
Progenitor Cell Therapy
Proteolix
Proximagen Group
Psynova Neurotech
Public Sector Pension Investment Board
Puma Biotechnology
Pyro Pharmaceuticals
QLT
Qualitest Pharmaceuticals
QuantRx Biomedical
Quest Diagnostics
Questcor Pharmaceuticals
Quidel
Radiancy
Radiation Therapy Services
Radius Health
Raptor Pharmaceutical
Reckitt Benckiser
Research Pharmaceutical Services
Roche
Pharma and Biotech M&A Trends 2009-2014 (From Issuu) Page 14/21
ReportLinker Find Industry reports, Company profilesand Market Statistics
>> Get this Report Now by email!
Rosetta Genomics
Rules-Based Medicine
RXi Pharmaceuticals
Safeguard Scientifics
Sanofi-Aventis
Sanofi
Santarus
Savient Pharmaceuticals
Schering-Plough
Schiff Nutrition International
Scientific Nanomedicine
Scientx
Senior Scientific
Sepracor
Shire Pharmaceuticals
Sight Science
Sigma-Aldrich
Sirius Laboratories
SkinMedica
Sloning BioTechnology
Smith & Nephew
Solta Medical
Solvay
Somanetics
Somaxon Pharmaceuticals
Sonkei Pharmaceuticals
Sonora Medical Systems
SonoSite
Southern Medical Acquisition
Southern Medical and Mobility
Spear Pharmaceuticals
Specifar Pharma
Spectrum Pharmaceuticals
SRI Surgical Express
St Jude Medical
Stericycle
Stryker
Sucampo AG
Sucampo Pharmaceuticals
Sun City Cardiac Center Associates
Sun Pharma Global
Sun Pharmaceutical
Sunovion Pharmaceuticals
SuperGen
Sycamore Films
Symphony Allegro
Symphony Capital
Symphony Dynamo
Pharma and Biotech M&A Trends 2009-2014 (From Issuu) Page 15/21
ReportLinker Find Industry reports, Company profilesand Market Statistics
>> Get this Report Now by email!
Symphony Icon
Symyx Technologies
Synageva BioPharma
Synergy Health
Synergy Pharmaceuticals
Syneron
Synovis Life Technologies
SyntheMed
Synthes
SynthRx
Systems Medicine
TAG Minerals
Talecris Biotherapeutics
Taligen Therapeutics
Tamandare Explorations
Targanta Therapeutics
Taro Pharmaceuticals
Teleflex
Tepnel Life Sciences
Teva Pharmaceutical Industries
The Carlyle Group
The Medicines Company
Theraclone Sciences
Theragenics
TherapeuticsMD
Thermo Fisher Scientific
ThermoGenesis
Thomas Medical
Thoratec
Tolmar
TomoTherapy
TONIX Pharmaceuticals
Tornier
TorreyPines Therapeutics
TotipotentRx
Tourtellotte Solutions
TPG Capital
Transave
Trimeris
Trinity Biotech
Trius Therapeutics
TrovaGene
Trubion
UniQure
Upsher-Smith
Urchin Merger Sub
US Oncology
Uteron Pharma
Pharma and Biotech M&A Trends 2009-2014 (From Issuu) Page 16/21
ReportLinker Find Industry reports, Company profilesand Market Statistics
>> Get this Report Now by email!
Valeant Pharmaceuticals
ValiRx
Varian Medical Systems
Vascular Solutions
Vasogen
VaxGen
VelQuest
Vertebron
Vertex Pharmaceuticals
VGX Pharmaceuticals
Vicept Therapeutics
Viking Systems
ViroChem Pharma
Viropharma
Visual Sonics
Vital Signs
VitamedMD
VNUS Medical Technologies
VolitionRX
Waban Software Group
Warburg Pincus
Warner Chilcott
Watson Pharmaceuticals
Wellness Center USA
Wellpoint
William Demant Holding
World Wide Relics
Wright Medical
WuXi PharmaTech
Wyeth
Yantai Tianzheng Pharmaceutical
YM BioSciences
Zenara Pharma
Zerusa
Zoll Medical
ZymoGenetics
ZyStor Therapeutics
7.3. By industry sector
Academic
Agricultural
Animal Health
Bigbiotech
Bigpharma
Biotech
Consumer health
Drug delivery
Medical device
Diagnostic
Pharma and Biotech M&A Trends 2009-2014 (From Issuu) Page 17/21
ReportLinker Find Industry reports, Company profilesand Market Statistics
>> Get this Report Now by email!
Financial
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Upgrade Order Form ' Subscription Access Products
The following appendices are available in a accompanying volume.
Appendices
Appendix 1 ' Company A-Z
Appendix 2 ' By industry sector
Academic
Agricultural
Animal Health
Big pharma
Big biotech
Biotech
Consumer health
Drug delivery
Medical device
Diagnostic
Financial
Generic pharma
Government
Non-profit
Pharmaceutical
Research tools
Services
Specialty pharma
Appendix 3 ' M&A dealmaking references
Appendix 4 ' Resources
Appendix 5 ' Deal type definitions
Appendix 6 ' Example M&A contract document
TABLE OF FIGURES
Figure 1: Definition of merger and acquisition
Figure 2: Trends in M&A deal announcements, 2009-2014
Pharma and Biotech M&A Trends 2009-2014 (From Issuu) Page 18/21
ReportLinker Find Industry reports, Company profilesand Market Statistics
>> Get this Report Now by email!
Figure 3: M&A deals signed at each phase of development, 2009-2014
Figure 4: Key recent M&A trends ' 2009 to present
Figure 5: Recent Japanese M&A
Figure 6: Recent 'option to acquire' deals
Figure 7: Situations where M&A can prove useful
Figure 8: Recent partnering deals involving equity participation in the licensor
Figure 9: Equity investments converting to acquisitions
Figure 10: Johnson & Johnson's growth through M&A
Figure 11: Novartis's growth through M&A since 2000
Figure 12: Shire's M&A history
Figure 13: Amgen's biotech-biotech acquisition trail
Figure 14: Private equity M&A activity, 2009-2014
Figure 15: Issues in implementing M&A agreements
Figure 16: Joint venture agreements, 2009-2014
Figure 17: Recent joint ventures in the biopharma sector
Figure 18: Future trends in M&A in biopharma
Figure 19: Components of the acquisition deal structure
Figure 20: Components of the merger deal structure
Figure 21: Top M&A deals by value since 2009
Figure 22: Top merger deals by value since 2009
Figure 23: Most active M&A dealmakers Jan 2009- May 2014
Figure 24: Big pharma ' top 50 ' M&A deals 2009 to mid 2014
Figure 25: Big pharma M&A deal frequency - 2009 to mid 2014
Figure 26: Big biotech ' top 50 ' M&A deals 2009 to mid 2014
Figure 27: Big biotech M&A deal frequency - 2009 to mid 2014
Pharma and Biotech M&A Trends 2009-2014 (From Issuu) Page 19/21
ReportLinker Find Industry reports, Company profilesand Market Statistics
>> Get this Report Now by email!Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require.
Product Formats Please select the product formats and the quantity you require.
Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________
Pharma and Biotech M&A Trends 2009-2014
1 User License--USD 2 995.00 Quantity: _____
CD-ROM--USD 3 495.00 Quantity: _____
2-5 User License--USD 4 495.00 Quantity: _____
Site License--USD 8 995.00 Quantity: _____
Corporate License--USD 14 995.00 Quantity: _____
Pharma and Biotech M&A Trends 2009-2014 (From Issuu) Page 20/21
ReportLinker Find Industry reports, Company profilesand Market Statistics
>> Get this Report Now by email!Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card
Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer
Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check
UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Customer signature:
Pharma and Biotech M&A Trends 2009-2014 (From Issuu) Page 21/21